273 related articles for article (PubMed ID: 31744005)
1. Sixteen-Week Interventional Study to Evaluate the Clinical Effects and Safety of Rivastigmine Capsules in Chinese Patients with Alzheimer's Disease.
Jia J; Ji Y; Feng T; Ye Q; Peng D; Kuang W; Ning Y; Liang Z; Fan D; Wei W; Li Y; Xiao S
J Alzheimers Dis; 2019; 72(4):1313-1322. PubMed ID: 31744005
[TBL] [Abstract][Full Text] [Related]
2. Rivastigmine for Alzheimer's disease.
Birks JS; Grimley Evans J
Cochrane Database Syst Rev; 2015 Apr; (4):CD001191. PubMed ID: 25858345
[TBL] [Abstract][Full Text] [Related]
3. Rivastigmine for Alzheimer's disease.
Birks J; Grimley Evans J; Iakovidou V; Tsolaki M; Holt FE
Cochrane Database Syst Rev; 2009 Apr; (2):CD001191. PubMed ID: 19370562
[TBL] [Abstract][Full Text] [Related]
4. A 48-Week, Multicenter, Open-Label, Observational Study Evaluating Oral Rivastigmine in Patients with Mild-to-Moderate Alzheimer's Disease in Taiwan.
Chang CC; Peng GS; Lai TJ; Li CH; Liu CK
Adv Ther; 2019 Jun; 36(6):1455-1464. PubMed ID: 30953330
[TBL] [Abstract][Full Text] [Related]
5. Rivastigmine Patch in Chinese Patients with Probable Alzheimer's disease: A 24-week, Randomized, Double-Blind Parallel-Group Study Comparing Rivastigmine Patch (9.5 mg/24 h) with Capsule (6 mg Twice Daily).
Zhang ZX; Hong Z; Wang YP; He L; Wang N; Zhao ZX; Zhao G; Shang L; Weisskopf M; Callegari F; Strohmaier C
CNS Neurosci Ther; 2016 Jun; 22(6):488-96. PubMed ID: 27012596
[TBL] [Abstract][Full Text] [Related]
6. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group.
Raskind MA; Cyrus PA; Ruzicka BB; Gulanski BI
J Clin Psychiatry; 1999 May; 60(5):318-25. PubMed ID: 10362441
[TBL] [Abstract][Full Text] [Related]
7. Safety/Tolerability and efficacy of rivastigmine in taiwanese patients with Alzheimer's disease: a prospective post-marketing surveillance study.
Chiu PY; Dai DE; Hsu HP; Lee C; Lin JJ; Kuo HC; Huang YC; Liu YC; Tsai CP
Clin Drug Investig; 2009; 29(11):729-38. PubMed ID: 19813776
[TBL] [Abstract][Full Text] [Related]
8. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study.
Cummings JL; Koumaras B; Chen M; Mirski D;
Am J Geriatr Pharmacother; 2005 Sep; 3(3):137-48. PubMed ID: 16257816
[TBL] [Abstract][Full Text] [Related]
9. Rivastigmine for dementia associated with Parkinson's disease.
Emre M; Aarsland D; Albanese A; Byrne EJ; Deuschl G; De Deyn PP; Durif F; Kulisevsky J; van Laar T; Lees A; Poewe W; Robillard A; Rosa MM; Wolters E; Quarg P; Tekin S; Lane R
N Engl J Med; 2004 Dec; 351(24):2509-18. PubMed ID: 15590953
[TBL] [Abstract][Full Text] [Related]
10. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
[TBL] [Abstract][Full Text] [Related]
11. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B
Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer's dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial.
Park KW; Kim EJ; Han HJ; Shim YS; Kwon JC; Ku BD; Park KH; Yi HA; Kim KK; Yang DW; Lee HW; Kang H; Kwon OD; Kim S; Lee JH; Chung EJ; Park SW; Park MY; Yoon B; Kim BC; Seo SW; Choi SH
PLoS One; 2017; 12(8):e0182123. PubMed ID: 28786987
[TBL] [Abstract][Full Text] [Related]
13. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.
Wolfson C; Oremus M; Shukla V; Momoli F; Demers L; Perrault A; Moride Y
Clin Ther; 2002 Jun; 24(6):862-86; discussion 837. PubMed ID: 12117079
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of the 10 cm
Chang CC; Chan L; Chou HH; Yang YW; Chen TF; Chen TB; Chen CI; Yang A; Hu CJ
Adv Ther; 2021 Oct; 38(10):5286-5301. PubMed ID: 34506009
[TBL] [Abstract][Full Text] [Related]
15. The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis.
Kobayashi H; Ohnishi T; Nakagawa R; Yoshizawa K
Int J Geriatr Psychiatry; 2016 Aug; 31(8):892-904. PubMed ID: 26680338
[TBL] [Abstract][Full Text] [Related]
16. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.
Articus K; Baier M; Tracik F; Kühn F; Preuss UW; Kurz A
Int J Clin Pract; 2011 Jul; 65(7):790-6. PubMed ID: 21645184
[TBL] [Abstract][Full Text] [Related]
17. Rivastigmine for Alzheimer's disease.
Birks J; Grimley Evans J ; Iakovidou V; Tsolaki M
Cochrane Database Syst Rev; 2000; (4):CD001191. PubMed ID: 11034705
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of higher-dose 13.3 mg/24 h (15 cm2) rivastigmine patch on the Alzheimer's Disease Assessment Scale-cognitive subscale: domain and individual item analysis.
Alva G; Isaacson R; Sadowsky C; Grossberg G; Meng X; Somogyi M
Int J Geriatr Psychiatry; 2014 Sep; 29(9):920-7. PubMed ID: 24549933
[TBL] [Abstract][Full Text] [Related]
19. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.
Winblad B; Cummings J; Andreasen N; Grossberg G; Onofrj M; Sadowsky C; Zechner S; Nagel J; Lane R
Int J Geriatr Psychiatry; 2007 May; 22(5):456-67. PubMed ID: 17380489
[TBL] [Abstract][Full Text] [Related]
20. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
